Satellos Bioscience Inc. (MSCLF)
- Previous Close
0.3800 - Open
0.3500 - Bid 0.4123 x --
- Ask 0.4318 x --
- Day's Range
0.3500 - 0.3800 - 52 Week Range
0.2200 - 0.5700 - Volume
6,000 - Avg. Volume
10,433 - Market Cap (intraday)
48.993M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.37
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
satellos.comRecent News: MSCLF
Performance Overview: MSCLF
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MSCLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MSCLF
Valuation Measures
Market Cap
48.68M
Enterprise Value
14.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.28%
Return on Equity (ttm)
-72.15%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.89M
Diluted EPS (ttm)
-0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
39.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.25M